Tributyltin and triphenyltin isothiocyanates down-regulate immune check-point receptors, but not HLA G in human triple-negative breast carcinoma MDA-MB-231 cell line

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F19%3A43878188" target="_blank" >RIV/62157124:16370/19:43878188 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Tributyltin and triphenyltin isothiocyanates down-regulate immune check-point receptors, but not HLA G in human triple-negative breast carcinoma MDA-MB-231 cell line

Original language description

Introduction Programmed Death 1 receptor (PD-1) is expressed in activated T-lymphocytes, B-lymphocytes, mononuclear cells, NK cells and some dendritic cells. As a consequence of PD-L1 ligand binding to PD-1 is down-regulation of T-cell activity. Human leukocyte antigen G (HLA-G) is an immunotolerant nonclassical major histocompatibility complex Class Ib molecule, overexpressed in tumors and involved in cancer immune evasion. We combined anticancer/genotoxic properties of two chemically different types of molecules, triorganotins and isothiocyanate,into tributyltin isothiocyanate (TBT-ITC) and triphenyltin isothiocyanate (TPT-ITC) and recently have shown their genotoxic effects in human breast carcinoma MCF 7 and MDA-MB-231 cell lines. In this study, we demonstrate immunomodulatory properties of their non-genotoxic concentrations in tripple negative human breast cancer cell line MDA-MB-231. Material and Method To select the optimal compounds concentrations that do not affect cell viability, the MTT test has been used. Conventional comet assay and its modification ? incubation of cells with styrene oxide (StO) were used for the detection of DNA damage as DNA breakage as well as DNA crosslinks formation. PDL-1 and HLA G expression were determined by flow cytometry. Results and Discussion 100 nM concentration of studied compounds has been selected for further in vitro experiments based on MTT test for 48 h. This concentration kept the viability of cells over 93%. Comet assay did not reveal the presence of DNA breaks or crosslinks in MDA-MB-231 cells after 24 h treatment with both ITC derivatives, indicating their non genotoxic potential at low 100 nM concentrations. Immune-regulatory properties of tested derivatives were demonstrated by flow cytometry and displayed down-regulation of PD-L1 molecule after 24 hour incubation with 100 nM concentration of both triorganotin isothiocyanates. However, these compounds did not modulate HLA G expression. Conclusion Serious interests in novel organotin compounds are undoubtebly increasing due to their possible use in clinical oncology. Here, we demonstrated down-regulation of an immune regulatory molecule that suppresses the anticancer tumor PD-L1 response on the surface of MDA-MB-231 cells after TBT-ITC and TPT-ITC treatment. These triorganotin compounds did not alter HLA G expression.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

30107 - Medicinal chemistry

Project

—

Continuities

S - Specificky vyzkum na vysokych skolach

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů